NeOnc closes strategic acquisition of advanced AI, 3D bioprinting IP

NeOnc Technologies (NTHI) announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers. The newly acquired IP, which includes U.S. Patent No. 11,788,057 B2, allows NeOnc to create highly sophisticated, patient-derived 3D brain tumor models. By applying proprietary AI and quantum modeling algorithms to these realistic biological environments, the company can now perform high-throughput screening of therapeutic candidates with greater speed and accuracy. The technology is designed to de-risk and shorten the preclinical development timeline, identifying the most promising drug candidates for clinical trials more efficiently.